



Clinical trial results:

A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2019-003383-47 |
| Trial protocol | IT |
| Global end of trial date | 12 July 2022 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 19 April 2023 |
| First version publication date | 19 April 2023 |

Trial information

Trial identification

| | |
|-----------------------|--------------|
| Sponsor protocol code | TAK-079-1005 |
|-----------------------|--------------|

Additional study identifiers

| | |
|------------------------------------|-----------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04159805 |
| WHO universal trial number (UTN) | U1111-1234-4442 |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Takeda |
| Sponsor organisation address | 95 Hayden Avenue, Lexington, United States, MA 02421 |
| Public contact | Study Director, Takeda, +1 877-825-3327, TrialDisclosures@takeda.com |
| Scientific contact | Study Director, Takeda, +1 877-825-3327, TrialDisclosures@takeda.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 12 July 2022 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|--------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 12 July 2022 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this trial is to evaluate the safety and tolerability of TAK-079 in participants with generalized myasthenia gravis (MG) who are receiving stable background therapy for MG.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 14 January 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Canada: 2 |
| Country: Number of subjects enrolled | Poland: 5 |
| Country: Number of subjects enrolled | Serbia: 17 |
| Country: Number of subjects enrolled | Spain: 4 |
| Country: Number of subjects enrolled | United States: 8 |
| Worldwide total number of subjects | 36 |
| EEA total number of subjects | 9 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 31 |
| From 65 to 84 years | 5 |

| | |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at 15 investigative sites in the United States, Spain, Poland, Serbia, and Canada from 14 January 2020 to 12 July 2022.

Pre-assignment

Screening details:

Participants with a diagnosis of Myasthenia Gravis (MG) were enrolled in 1:1:1 ratio to receive TAK-079 matching placebo, TAK-079 300 mg or TAK-079 600 mg in combination with standard background therapy.

Period 1

| | |
|------------------------------|--|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Data analyst, Carer |

Arms

| | |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | TAK-079 Placebo-matching |

Arm description:

TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | TAK-079 Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

TAK-079 placebo-matching SC injection

| | |
|------------------|----------------|
| Arm title | TAK-079 300 mg |
|------------------|----------------|

Arm description:

TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | TAK-079 |
| Investigational medicinal product code | |
| Other name | Mezagitamab |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

TAK-079 SC injection

| | |
|------------------|----------------|
| Arm title | TAK-079 600 mg |
|------------------|----------------|

Arm description:

TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------------------|
| Investigational medicinal product name | TAK-079 |
| Investigational medicinal product code | |
| Other name | Mezagitamab |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

TAK-079 SC injection

| Number of subjects in period 1 | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---------------------------------------|--------------------------|----------------|----------------|
| Started | 12 | 12 | 12 |
| Completed | 12 | 10 | 10 |
| Not completed | 0 | 2 | 2 |
| Consent withdrawn by subject | - | 2 | 2 |

Baseline characteristics

Reporting groups

| | |
|---|--------------------------|
| Reporting group title | TAK-079 Placebo-matching |
| Reporting group description: TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks. | |
| Reporting group title | TAK-079 300 mg |
| Reporting group description: TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks. | |
| Reporting group title | TAK-079 600 mg |
| Reporting group description: TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks. | |

| Reporting group values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|------------------------------------|--------------------------|----------------|----------------|
| Number of subjects | 12 | 12 | 12 |
| Age Categorical Units: Subjects | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Age continuous Units: years arithmetic mean standard deviation | 46.5 ± 18.03 | 45.3 ± 12.47 | 56.3 ± 14.42 |
| Gender categorical Units: Subjects | | | |
| Female | 9 | 6 | 7 |
| Male | 3 | 6 | 5 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 2 | 0 | 1 |
| Not Hispanic or Latino | 9 | 12 | 11 |
| Unknown or Not Reported | 1 | 0 | 0 |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 |
| White | 10 | 12 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 |
| Region of Enrollment Units: Subjects | | | |
| Canada Canada | 0 | 1 | 1 |
| Poland Poland | 1 | 2 | 2 |
| Serbia Serbia | 5 | 7 | 5 |
| Spain Spain | 3 | 0 | 1 |

| | | | |
|-----------------------------|---|---|---|
| United States United States | 3 | 2 | 3 |
|-----------------------------|---|---|---|

| | | | |
|--|-------------------|-------------------|--------------------|
| Weight Units: kg arithmetic mean standard deviation | 85.11 ± 25.607 | 86.28 ± 21.132 | 88.38 ± 25.672 |
| Height Units: cm arithmetic mean standard deviation | 164.67 ± 9.435 | 175.39 ± 8.911 | 171.38 ± 10.910 |
| Quantitative Myasthenia Gravis (QMG) Scale Score at Baseline | | | |
| Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. | | | |
| Units: score on a scale arithmetic mean standard deviation | 11.4 ± 5.21 | 12.9 ± 6.47 | 12.8 ± 4.26 |
| Myasthenia Gravis Composite (MGC) Scale Score at Baseline | | | |
| An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Each question is graded on 4 levels of impact from normal to severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. | | | |
| Units: score on a scale arithmetic mean standard deviation | 14.7 ± 5.80 | 16.8 ± 6.58 | 15.3 ± 6.00 |
| Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score at Baseline | | | |
| A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the patient tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. | | | |
| Units: score on a scale arithmetic mean standard deviation | 11.5 ± 4.15 | 17.1 ± 6.76 | 13.9 ± 4.72 |
| Body Mass Index (BMI) | | | |
| BMI=[weight(kg) / height(m)^2]. | | | |
| Units: kg/m^2 arithmetic mean standard deviation | 31.33 ± 8.867 | 27.74 ± 4.852 | 30.22 ± 9.315 |
| Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score at Baseline | | | |
| Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. | | | |
| Units: score on a scale arithmetic mean standard deviation | 7.9 ± 1.78 | 9.3 ± 2.49 | 8.4 ± 2.23 |
| Reporting group values | Total | | |
| Number of subjects | 36 | | |

| | | | |
|---|----|--|--|
| Age Categorical Units: Subjects | | | |
| Age continuous Units: years arithmetic mean standard deviation | - | | |
| Gender categorical Units: Subjects | | | |
| Female | 22 | | |
| Male | 14 | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 3 | | |
| Not Hispanic or Latino | 32 | | |
| Unknown or Not Reported | 1 | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | |
| Asian | 1 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 1 | | |
| White | 33 | | |
| More than one race | 0 | | |
| Unknown or Not Reported | 1 | | |
| Region of Enrollment Units: Subjects | | | |
| Canada Canada | 2 | | |
| Poland Poland | 5 | | |
| Serbia Serbia | 17 | | |
| Spain Spain | 4 | | |
| United States United States | 8 | | |
| Weight Units: kg arithmetic mean standard deviation | - | | |
| Height Units: cm arithmetic mean standard deviation | - | | |
| Quantitative Myasthenia Gravis (QMG) Scale Score at Baseline | | | |
| Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. | | | |
| Units: score on a scale arithmetic mean standard deviation | - | | |
| Myasthenia Gravis Composite (MGC) Scale Score at Baseline | | | |
| An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Each question is graded on 4 levels of impact from normal to severe with a total score of | | | |

| | | | |
|--|---|--|--|
| 0 to 50; the higher score indicates worse MG disease activity. | | | |
| Units: score on a scale arithmetic mean standard deviation | - | | |
| Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score at Baseline | | | |
| A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the patient tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. | | | |
| Units: score on a scale arithmetic mean standard deviation | - | | |
| Body Mass Index (BMI) | | | |
| BMI=[weight(kg) / height(m)^2]. | | | |
| Units: kg/m^2 arithmetic mean standard deviation | - | | |
| Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score at Baseline | | | |
| Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. | | | |
| Units: score on a scale arithmetic mean standard deviation | - | | |

End points

End points reporting groups

| | |
|---|--------------------------|
| Reporting group title | TAK-079 Placebo-matching |
| Reporting group description: TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks. | |
| Reporting group title | TAK-079 300 mg |
| Reporting group description: TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks. | |
| Reporting group title | TAK-079 600 mg |
| Reporting group description: TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks. | |

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 Discontinuation

| | |
|--|---|
| End point title | Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 Discontinuation ^[1] |
| End point description: AE=any untoward medical occurrence in clinical investigation participant administered drug;does not necessarily have to have causal relationship with this treatment.TEAE=AE with onset that occurs after receiving study drug.SAE is AE resulting in any of following outcomes or deemed significant for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience(immediate risk of dying); persistent or significant disability/incapacity;congenital anomaly.Severity of TEAEs was graded using National cancer institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE) version 4.03 definitions of Grade 1 through Grade 5 where Grade 1=mild symptoms,Grade 2=moderate symptoms,Grade 3=Severe or medically significant but not immediately life-threatening,Grade 4=life-threatening consequences and Grade 5=death related to AEs.Percentages are rounded off to whole number at single decimal. Safety Analysis Set=participants receiving at least 1 dose of study drug. | |
| End point type | Primary |
| End point timeframe: From signing the informed consent form up to end of long-term follow-up (up to Week 32) | |
| Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive statistical analysis was performed for this endpoint. | |

| End point values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | |
|---------------------------------------|--------------------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| TEAE | 66.7 | 75.0 | 91.7 | |
| SAE | 8.3 | 8.3 | 8.3 | |
| Grade 3 or Higher TEAEs | 16.7 | 8.3 | 8.3 | |
| AE Leading to TAK-079 Discontinuation | 0.0 | 0.0 | 0.0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score

| | |
|-----------------|---|
| End point title | Change From Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score |
|-----------------|---|

End point description:

Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Negative change indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for the analysis. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment. n=Number analysed is the number of participants available for analysis at the specified timepoint. 9999=Data not reported for 0 participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 32

| End point values | TAK-079 Placebo- matching | TAK-079 300 mg | TAK-079 600 mg | |
|---|---------------------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Change From Baseline at Week 4(n=12,12,12) | -2.8 (± 2.67) | -2.5 (± 2.47) | -1.8 (± 1.66) | |
| Change From Baseline at Week 6(n=12,11,11) | -4.0 (± 2.73) | -4.2 (± 2.64) | -2.3 (± 2.15) | |
| Change From Baseline at Week 8(n=12,11,12) | -3.8 (± 2.80) | -4.3 (± 3.10) | -2.0 (± 3.16) | |
| Change From Baseline at Week 10(n=11,11,11) | -4.0 (± 3.52) | -5.0 (± 2.41) | -2.0 (± 2.79) | |
| Change From Baseline at Week 12(n=11,11,12) | -4.2 (± 3.19) | -4.2 (± 2.56) | -2.5 (± 2.68) | |
| Change From Baseline at Week 14(n=11,10,10) | -4.0 (± 4.38) | -4.8 (± 2.20) | -2.0 (± 3.30) | |
| Change From Baseline at Week 16(n=10,10,10) | -4.1 (± 3.21) | -4.3 (± 2.79) | -3.1 (± 3.48) | |
| Change From Baseline at Week 20(n=0,8,11) | 9999 (± 9999) | -3.9 (± 3.60) | -2.9 (± 3.11) | |
| Change From Baseline at Week 24(n=0,9,9) | 9999 (± 9999) | -4.1 (± 3.62) | -3.0 (± 3.57) | |
| Change From Baseline at Week 28(n=0,10,9) | 9999 (± 9999) | -3.9 (± 3.96) | -3.1 (± 3.37) | |
| Change From Baseline at Week 32(n=0,9,8) | 9999 (± 9999) | -2.3 (± 4.61) | -2.8 (± 3.99) | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 2 |
| Statistical analysis description: Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.299 ^[2] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.01 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.94 |
| upper limit | 2.97 |

Notes:

[2] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 300 mg v TAK-079 Placebo-matching |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.772 ^[3] |
| Method | MMRM |
| Parameter estimate | Difference in Least Square (LS) Mean |
| Point estimate | 0.29 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.72 |
| upper limit | 2.3 |

Notes:

[3] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|------------------------|
| Statistical analysis title | Statistical Analysis 5 |
| Statistical analysis description: Change From Baseline at Week 8 | |

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.887 ^[4] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.18 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.82 |
| upper limit | 2.45 |

Notes:

[4] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 6 |
| Statistical analysis description: Change From Baseline at Week 8 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.162 ^[5] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.76 |
| upper limit | 4.36 |

Notes:

[5] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 4 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.091 ^[6] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.86 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.32 |
| upper limit | 4.04 |

Notes:

[6] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 3 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 6

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.924 ^[7] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.11 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.34 |
| upper limit | 2.13 |

Notes:

[7] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 7 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.784 ^[8] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.36 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.01 |
| upper limit | 2.29 |

Notes:

[8] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 9 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.724 ^[9] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.42 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.98 |
| upper limit | 2.82 |

Notes:

[9] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 8 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.166 ^[10] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.79 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.79 |
| upper limit | 4.37 |

Notes:

[10] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 10 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.124 ^[11] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.81 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.52 |
| upper limit | 4.14 |

Notes:

[11] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 11 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.856 ^[12] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.29 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.91 |
| upper limit | 3.48 |

Notes:

[12] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 13 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.944 ^[13] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.11 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.14 |
| upper limit | 3.37 |

Notes:

[13] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.292 ^[14] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.64 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.48 |
| upper limit | 4.76 |

Notes:

[14] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 14 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.589 ^[15] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.85 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.33 |
| upper limit | 4.02 |

Notes:

[15] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

Secondary: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score

| | |
|-----------------|--|
| End point title | Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score |
|-----------------|--|

End point description:

Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Negative change indicates improvement. MMRM was used for the analysis. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment. n=Number analysed is the number of participants available for analysis at the specified timepoint. 9999=Dta was not collected for 0 participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 32

| End point values | TAK-079 Placebo- matching | TAK-079 300 mg | TAK-079 600 mg | |
|---|---------------------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Change From Baseline at Week 4(n=12,12,12) | -1.0 (± 2.34) | -2.0 (± 2.70) | -0.2 (± 2.89) | |
| Change From Baseline at Week 6(n=11,12,12) | -0.9 (± 1.76) | -2.5 (± 3.24) | -1.3 (± 3.10) | |
| Change From Baseline at Week 8(n=12,11,11) | -1.0 (± 2.30) | -3.4 (± 3.35) | -0.9 (± 3.27) | |
| Change From Baseline at Week 10(n=11,11,11) | -1.4 (± 2.87) | -3.2 (± 3.09) | -0.7 (± 4.03) | |
| Change From Baseline at Week 12(n=11,11,12) | -2.8 (± 2.68) | -3.9 (± 2.55) | -0.8 (± 3.51) | |
| Change From Baseline at Week 14(n=11,10,10) | -1.9 (± 3.11) | -3.5 (± 2.51) | -0.6 (± 4.65) | |
| Change From Baseline at Week 16(n=10,10,10) | -1.2 (± 3.22) | -3.3 (± 3.43) | -0.3 (± 4.81) | |
| Change From Baseline at Week 20(n=0,8,11) | 9999 (± 9999) | -1.9 (± 3.56) | -0.5 (± 4.27) | |
| Change From Baseline at Week 24(n=0,9,9) | 9999 (± 9999) | -2.2 (± 4.47) | -0.6 (± 3.78) | |
| Change From Baseline at Week 28(n=0,10,9) | 9999 (± 9999) | -1.7 (± 3.80) | -0.8 (± 4.52) | |
| Change From Baseline at Week 32(n=0,9,8) | 9999 (± 9999) | -0.7 (± 4.27) | -0.1 (± 4.79) | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 3 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.463 ^[16] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.94 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.53 |
| upper limit | 1.65 |

Notes:

[16] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 2 |
| Statistical analysis description: Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.418 ^[17] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.34 |
| upper limit | 3.14 |

Notes:

[17] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.406 ^[18] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.93 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.17 |
| upper limit | 1.31 |

Notes:

[18] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 6 |
| Statistical analysis description: Change From Baseline at Week 8 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.687 ^[19] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.1 |
| upper limit | 3.13 |

Notes:

[19] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 5 |
| Statistical analysis description: Change From Baseline at Week 8 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.17 ^[20] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.41 |
| upper limit | 0.82 |

Notes:

[20] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 4 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.936 ^[21] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.1 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.7 |
| upper limit | 2.49 |

Notes:

[21] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 7 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.374 ^[22] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.24 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.05 |
| upper limit | 1.57 |

Notes:

[22] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 10 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.106 ^[23] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 2.12 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.48 |
| upper limit | 4.71 |

Notes:

[23] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 9 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.69 ^[24] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.51 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.12 |
| upper limit | 2.09 |

Notes:

[24] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 8 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.478 ^[25] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.82 |
| upper limit | 3.8 |

Notes:

[25] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 13 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.431 ^[26] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.37 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.91 |
| upper limit | 2.17 |

Notes:

[26] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.144 ^[27] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 2.19 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.81 |
| upper limit | 5.18 |

Notes:

[27] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 11 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.547 ^[28] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.89 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.89 |
| upper limit | 2.12 |

Notes:

[28] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 14 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.488 |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.34 |
| upper limit | 4.74 |

Secondary: Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Score

| | |
|-----------------|---|
| End point title | Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Score |
|-----------------|---|

End point description:

An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Each question is graded on 4 levels of impact from normal to severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment. n=Number analysed is the number of participants available for analysis at the specified timepoint. 9999=Data was not reported for 0 participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 32

| End point values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | |
|---|--------------------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Change From Baseline at Week 4(n=12,12,12) | -4.2 (± 3.69) | -4.9 (± 3.82) | -1.1 (± 5.92) | |
| Change From Baseline at Week 6(n=12,11,11) | -7.3 (± 4.29) | -6.1 (± 5.24) | -4.9 (± 4.74) | |
| Change From Baseline at Week 8(n=11,11,12) | -5.5 (± 4.03) | -7.4 (± 4.63) | -2.4 (± 6.10) | |
| Change From Baseline at Week 10(n=11,11,11) | -7.8 (± 5.86) | -7.6 (± 5.07) | -2.6 (± 6.55) | |
| Change From Baseline at Week 12(n=11,11,12) | -7.3 (± 5.00) | -8.5 (± 3.11) | -5.1 (± 5.11) | |
| Change From Baseline at Week 14(n=11,10,10) | -6.1 (± 6.52) | -9.7 (± 3.83) | -0.9 (± 8.25) | |

| | | | | |
|---|---------------|---------------|---------------|--|
| Change From Baseline at Week 16(n=10,10,10) | -6.6 (± 4.95) | -9.2 (± 5.18) | -2.9 (± 6.45) | |
| Change From Baseline at Week 20(n=0,8,11) | 9999 (± 9999) | -7.3 (± 5.20) | -2.6 (± 7.21) | |
| Change From Baseline at Week 24(n=0,9,9) | 9999 (± 9999) | -7.1 (± 5.78) | -3.3 (± 7.30) | |
| Change From Baseline at Week 28(n=0,10,9) | 9999 (± 9999) | -5.6 (± 6.40) | -4.1 (± 7.59) | |
| Change From Baseline at Week 32(n=0,9,8) | 9999 (± 9999) | -3.4 (± 8.13) | -2.5 (± 8.07) | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|---|---|
| Statistical analysis description: Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.855 ^[29] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.34 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.14 |
| upper limit | 3.45 |

Notes:

[29] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| Statistical analysis title | Statistical Analysis 6 |
|---|---|
| Statistical analysis description: Change From Baseline at Week 8 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.13 ^[30] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 3.26 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.02 |
| upper limit | 7.54 |

Notes:

[30] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 5 |
| Statistical analysis description: Change From Baseline at Week 8 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.662 ^[31] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.94 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.29 |
| upper limit | 3.41 |

Notes:

[31] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 4 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.154 ^[32] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 3.13 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.25 |
| upper limit | 7.5 |

Notes:

[32] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 3 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |

| | |
|---|------------------------|
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.41 ^[33] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.61 |
| upper limit | 6.2 |

Notes:

[33] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 2 |
| Statistical analysis description: Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.093 ^[34] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 3.19 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.56 |
| upper limit | 6.95 |

Notes:

[34] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|--|---|
| Statistical analysis title | Statistical Analysis 13 |
| Statistical analysis description: Change From Baseline at Week 16 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.677 ^[35] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.01 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.98 |
| upper limit | 3.95 |

Notes:

[35] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.08 ^[36] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 5.2 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.67 |
| upper limit | 11.06 |

Notes:

[36] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 11 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.764 ^[37] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.88 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.8 |
| upper limit | 5.05 |

Notes:

[37] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 10 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.158 ^[38] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 2.65 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.09 |
| upper limit | 6.4 |

Notes:

[38] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 9 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.909 ^[39] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.22 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.03 |
| upper limit | 3.6 |

Notes:

[39] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 8 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.039 ^[40] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 4.93 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.26 |
| upper limit | 9.6 |

Notes:

[40] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 14 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.055 ^[41] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 4.81 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.1 |
| upper limit | 9.73 |

Notes:

[41] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 7 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.586 ^[42] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.27 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.44 |
| upper limit | 5.98 |

Notes:

[42] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

Secondary: Change From Baseline in Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score

| | |
|--|---|
| End point title | Change From Baseline in Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score |
| End point description: | |
| A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the participant tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment. n=Number analysed is the number of participants available for analysis at the specified timepoint. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline up to Week 32 | |

| End point values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | |
|---|--------------------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Change From Baseline at Week 4(n=12,12,12) | -3.1 (± 3.85) | -3.9 (± 4.46) | -3.2 (± 4.43) | |
| Change From Baseline at Week 6(n=12,11,11) | -4.3 (± 4.11) | -5.8 (± 6.00) | -3.4 (± 3.53) | |
| Change From Baseline at Week 8(n=12,11,12) | -3.2 (± 4.00) | -5.6 (± 6.53) | -3.3 (± 3.74) | |
| Change From Baseline at Week 10(n=11,11,11) | -2.5 (± 6.12) | -6.3 (± 6.07) | -3.9 (± 3.70) | |
| Change From Baseline at Week 12(n=11,11,12) | -2.5 (± 5.32) | -6.1 (± 7.25) | -4.1 (± 4.40) | |
| Change From Baseline at Week 14(n=11,10,10) | -2.0 (± 7.06) | -6.4 (± 6.98) | -0.9 (± 5.49) | |
| Change From Baseline at Week 16(n=10,10,10) | -3.8 (± 4.44) | -5.8 (± 6.83) | -2.3 (± 6.43) | |
| Change From Baseline at Week 20(n=0,8,11) | 9999 (± 9999) | -3.3 (± 7.01) | -4.7 (± 5.48) | |
| Change From Baseline at Week 24(n=0,8,9) | 9999 (± 9999) | -7.1 (± 7.95) | -3.8 (± 5.31) | |
| Change From Baseline at Week 28(n=0,10,8) | 9999 (± 9999) | -4.8 (± 10.36) | -4.0 (± 6.16) | |
| Change From Baseline at Week 32(n=0,9,8) | 9999 (± 9999) | -6.2 (± 7.31) | -2.4 (± 4.78) | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Statistical Analysis 1 |
| Statistical analysis description: | |
| Change From Baseline at Week 4 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |

| | |
|---|------------------------|
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.78 ^[43] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.52 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.23 |
| upper limit | 4.27 |

Notes:

[43] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 3 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.984 ^[44] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.22 |
| upper limit | 4.14 |

Notes:

[44] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|---|---|
| Statistical analysis title | Statistical Analysis 4 |
| Statistical analysis description: Change From Baseline at Week 6 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.213 ^[45] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 2.44 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.47 |
| upper limit | 6.35 |

Notes:

[45] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 5 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 8

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.371 ^[46] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.97 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.4 |
| upper limit | 2.45 |

Notes:

[46] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 6 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 8

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.956 ^[47] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.11 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.01 |
| upper limit | 4.23 |

Notes:

[47] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 4

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.771 ^[48] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.99 |
| upper limit | 3.99 |

Notes:

[48] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 7 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.641 ^[49] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.06 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.65 |
| upper limit | 3.53 |

Notes:

[49] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 11 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.699 ^[50] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.14 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -7.07 |
| upper limit | 4.8 |

Notes:

[50] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 10 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.769 ^[51] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.68 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.37 |
| upper limit | 4 |

Notes:

[51] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 8 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.876 ^[52] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -0.33 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.61 |
| upper limit | 3.95 |

Notes:

[52] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 9 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.458 ^[53] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -1.86 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.91 |
| upper limit | 3.18 |

Notes:

[53] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 13 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.944 ^[54] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.55 |
| upper limit | 5.95 |

Notes:

[54] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.687 ^[55] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.1 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.41 |
| upper limit | 6.62 |

Notes:

[55] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 14 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 24 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.351 ^[56] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 2.48 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.87 |
| upper limit | 7.83 |

Notes:

[56] - From a MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

Secondary: Change From Baseline in Anti-acetylcholine Receptor (AChR) Antibody Levels

| | |
|-----------------|--|
| End point title | Change From Baseline in Anti-acetylcholine Receptor (AChR) Antibody Levels |
|-----------------|--|

End point description:

Clinical laboratory evaluations of anti-AChR antibodies were tested to monitor disease activity. MMRM was used for the analysis. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment. Subjects analysed is the number of participants available for analyses. n=Number analysed is the number of participants available for analysis at the specified timepoint. 9999=Data not reported for 0 participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 32

| End point values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | |
|--------------------------------------|--------------------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 10 | 12 | |
| Units: nmol/L | | | | |
| arithmetic mean (standard deviation) | | | | |

| | | | | |
|--|----------------------|----------------------|---------------------|--|
| Change From Baseline at Week 2(n=11,10,12) | -6.300 (± 25.3514) | -19.452 (± 50.5551) | -3.450 (± 5.7767) | |
| Change From Baseline at Week 3(n=11,10,12) | -3.989 (± 22.9732) | -14.821 (± 44.4776) | -2.509 (± 17.5221) | |
| Change From Baseline at Week 4(n=11,10,12) | -0.976 (± 11.7759) | -24.253 (± 51.2627) | -13.680 (± 87.1669) | |
| Change From Baseline at Week 5(n=11,10,12) | -8.199 (± 13.9571) | -32.251 (± 58.3701) | -9.831 (± 26.2188) | |
| Change From Baseline at Week 6(n=11,9,11) | -19.152 (± 49.2221) | -27.518 (± 52.6672) | -2.148 (± 23.2543) | |
| Change From Baseline at Week 7(n=11,9,11) | -11.235 (± 26.2159) | -33.261 (± 56.3495) | -9.882 (± 16.2972) | |
| Change From Baseline at Week 8(n=10,9,12) | -7.731 (± 27.8994) | -39.386 (± 72.3110) | -5.668 (± 10.4493) | |
| Change From Baseline at Week 10(n=10,9,11) | -37.473 (± 120.9186) | -37.083 (± 60.8092) | -6.654 (± 7.8236) | |
| Change From Baseline at Week 12(n=10,9,12) | -0.832 (± 31.0318) | -38.430 (± 64.4594) | -7.827 (± 11.2120) | |
| Change From Baseline at Week 14(n=9,8,10) | -12.729 (± 49.8823) | -40.771 (± 74.3624) | -8.058 (± 15.8407) | |
| Change From Baseline at Week 16(n=7,8,10) | -3.501 (± 9.8729) | -49.843 (± 77.6316) | -4.909 (± 8.8478) | |
| Change From Baseline at Week 20(n=0,7,11) | 9999 (± 9999) | -52.217 (± 83.1537) | -4.378 (± 7.7297) | |
| Change From Baseline at Week 24(n=0,7,9) | 9999 (± 9999) | -43.079 (± 77.4438) | -4.802 (± 10.5639) | |
| Change From Baseline at Week 28(n=0,8,9) | 9999 (± 9999) | -73.786 (± 111.0044) | -6.044 (± 11.3755) | |
| Change From Baseline at Week 32(n=0,7,8) | 9999 (± 9999) | -51.296 (± 67.3437) | -5.485 (± 11.8380) | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 2 |
|---|---|
| Statistical analysis description: | |
| Change From Baseline at Week 2 | |
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.328 ^[57] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -15.77 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -47.5 |
| upper limit | 15.96 |

Notes:

[57] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 2

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.09 ^[58] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -27.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -60.18 |
| upper limit | 4.38 |

Notes:

[58] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 3 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 3

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.441 ^[59] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -12.65 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -44.94 |
| upper limit | 19.63 |

Notes:

[59] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 4 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 3

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.931 ^[60] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 1.39 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -30.33 |
| upper limit | 33.12 |

Notes:

[60] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 5 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 4

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.087 ^[61] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -28.18 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -60.46 |
| upper limit | 4.11 |

Notes:

[61] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 6 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 4

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.783 ^[62] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 4.44 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -27.29 |
| upper limit | 36.16 |

Notes:

[62] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 7 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 5

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.077 ^[63] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -29.08 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -61.36 |
| upper limit | 3.21 |

Notes:

[63] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 10 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 6

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 1 ^[64] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -32.18 |
| upper limit | 32.19 |

Notes:

[64] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 9 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 6

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.4 ^[65] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -14.14 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -47.19 |
| upper limit | 18.91 |

Notes:

[65] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 8 |
|-----------------------------------|------------------------|

Statistical analysis description:

Change From Baseline at Week 5

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.33 ^[66] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -15.72 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -47.45 |
| upper limit | 16 |

Notes:

[66] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 11 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 7

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.117 ^[67] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -26.47 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -59.64 |
| upper limit | 6.69 |

Notes:

[67] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 15 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.815 ^[68] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -3.97 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -37.34 |
| upper limit | 29.4 |

Notes:

[68] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 14 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 8

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.215 ^[69] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -20.48 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -52.92 |
| upper limit | 11.95 |

Notes:

[69] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 13 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 8

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.005 ^[70] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -47.91 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -81.54 |
| upper limit | -14.29 |

Notes:

[70] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 7

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.436 ^[71] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -12.75 |

Confidence interval

| | |
|-------------|---------|
| level | 95 % |
| sides | 2-sided |
| lower limit | -44.94 |
| upper limit | 19.44 |

Notes:

[71] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 16 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 10

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.794 ^[72] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -4.31 |

Confidence interval

| | |
|-------------|---------|
| level | 95 % |
| sides | 2-sided |
| lower limit | -36.84 |
| upper limit | 28.22 |

Notes:

[72] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Change From Baseline at Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.033 ^[73] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -36.78 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -70.48 |
| upper limit | -3.08 |

Notes:

[73] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 21 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.001 ^[74] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -62.98 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -100.64 |
| upper limit | -25.31 |

Notes:

[74] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 20 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.036 ^[75] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -36.94 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -71.39 |
| upper limit | -2.48 |

Notes:

[75] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 19 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Week 14

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 300 mg |
| Number of subjects included in analysis | 21 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.002 ^[76] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -56.21 |

Confidence interval

| | |
|-------------|---------|
| level | 95 % |
| sides | 2-sided |
| lower limit | -91.69 |
| upper limit | -20.73 |

Notes:

[76] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 18 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Week 12

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.513 ^[77] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -10.79 |

Confidence interval

| | |
|-------------|---------|
| level | 95 % |
| sides | 2-sided |
| lower limit | -43.26 |
| upper limit | 21.67 |

Notes:

[77] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical Analysis 22 |
|-----------------------------------|-------------------------|

Statistical analysis description:

Week 16

| | |
|---|---|
| Comparison groups | TAK-079 Placebo-matching v TAK-079 600 mg |
| Number of subjects included in analysis | 23 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.13 ^[78] |
| Method | MMRM |
| Parameter estimate | Difference in LS Mean |
| Point estimate | -28.81 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -66.12 |
| upper limit | 8.51 |

Notes:

[78] - From MMRM analysis over all post-baseline visits, with the change from baseline as the outcome, treatment group, visit, and treatment-by-visit interaction as factors, and adjusted by baseline value and baseline-by-visit interaction.

Secondary: Change From Baseline in Anti- Muscle-specific Tyrosine Kinase (MuSK) Titer Levels

| | |
|-----------------|---|
| End point title | Change From Baseline in Anti- Muscle-specific Tyrosine Kinase (MuSK) Titer Levels |
|-----------------|---|

End point description:

Clinical laboratory evaluations of anti-MuSK antibodies were tested to monitor disease activity. Data is reported for participants who were positive for anti-MuSK antibodies at baseline. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment. Subjects analysed is the number of participants available for analyses. n=Number analysed is the number of participants available for analysis at the specified timepoint. 99999=SD was not estimable for 1 participant. 9999=Data was not reported for 0 participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 32

| End point values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | |
|---|--------------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1 | 2 | 0 ^[79] | |
| Units: titer | | | | |
| arithmetic mean (standard deviation) | | | | |
| Change From Baseline at Week 2(n=1,2,0) | 0.0 (± 99999) | -160.0 (± 226.27) | () | |
| Change From Baseline at Week 3(n=1,2,0) | 0.0 (± 99999) | -200.0 (± 169.71) | () | |
| Change From Baseline at Week 4(n=1,2,0) | 0.0 (± 99999) | -240.0 (± 339.41) | () | |
| Change From Baseline at Week 5(n=1,2,0) | 0.0 (± 99999) | -240.0 (± 339.41) | () | |
| Change From Baseline at Week 6(n=1,2,0) | 0.0 (± 99999) | -240.0 (± 339.41) | () | |
| Change From Baseline at Week 7(n=1,2,0) | 0.0 (± 99999) | -240.0 (± 339.41) | () | |

| | | | | |
|--|---------------|-------------------|----|--|
| Change From Baseline at Week 8(n=1,2,0) | 0.0 (± 99999) | -280.0 (± 395.98) | () | |
| Change From Baseline at Week 10(n=1,2,0) | 0.0 (± 99999) | -280.0 (± 395.98) | () | |
| Change From Baseline at Week 12(n=1,2,0) | 0.0 (± 99999) | -300.0 (± 424.26) | () | |
| Change From Baseline at Week 14(n=1,2,0) | 0.0 (± 99999) | -300.0 (± 424.26) | () | |
| Change From Baseline at Week 16(n=1,2,0) | 0.0 (± 99999) | -300.0 (± 424.26) | () | |
| Change From Baseline at Week 20(n=0,1,0) | 9999 (± 9999) | 0.0 (± 99999) | () | |
| Change From Baseline at Week 24(n=0,2,0) | 9999 (± 9999) | -310.0 (± 438.41) | () | |
| Change From Baseline at Week 28(n=0,2,0) | 9999 (± 9999) | -310.0 (± 438.41) | () | |
| Change From Baseline at Week 32(n=0,2,0) | 9999 (± 9999) | -310.0 (± 438.41) | () | |

Notes:

[79] - Data was not analyzed of this arm group.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With 2-point Reduction in MG-ADL Total Score

| | |
|-----------------|---|
| End point title | Percentage of Participants With 2-point Reduction in MG-ADL Total Score |
|-----------------|---|

End point description:

The percentage of responders with at least a 2-point reduction in MG-ADL total score from baseline is reported. MG-ADL is a participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Percentages are rounded off to whole number at the nearest decimal. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32

| End point values | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | |
|-----------------------------------|--------------------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| Week 4 | 50.00 | 75.00 | 58.33 | |
| Week 6 | 91.67 | 75.00 | 58.33 | |
| Week 8 | 83.33 | 66.67 | 66.67 | |
| Week 10 | 83.33 | 83.33 | 50.00 | |
| Week 12 | 75.00 | 75.00 | 50.00 | |
| Week 14 | 66.67 | 75.00 | 50.00 | |
| Week 16 | 66.67 | 66.67 | 33.33 | |

| | | | | |
|---------|-----|-------|-------|--|
| Week 20 | 0.0 | 66.67 | 58.33 | |
| Week 24 | 0.0 | 58.33 | 58.33 | |
| Week 28 | 0.0 | 58.33 | 58.33 | |
| Week 32 | 0.0 | 41.67 | 41.67 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With 3-point Reduction in QMG Total Score

| | |
|-----------------|--|
| End point title | Percentage of Participants With 3-point Reduction in QMG Total Score |
|-----------------|--|

End point description:

The percentage of responders with at least a 3-point reduction in QMG total score from baseline is reported. QMG is a physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Percentages are rounded off to whole number at the nearest decimal. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32

| End point values | TAK-079 Placebo- matching | TAK-079 300 mg | TAK-079 600 mg | |
|-----------------------------------|---------------------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| Week 4 | 25.00 | 50.00 | 16.67 | |
| Week 6 | 16.67 | 41.67 | 33.33 | |
| Week 8 | 33.33 | 66.67 | 33.33 | |
| Week 10 | 33.33 | 66.67 | 33.33 | |
| Week 12 | 41.67 | 75.00 | 25.00 | |
| Week 14 | 33.33 | 66.67 | 25.00 | |
| Week 16 | 33.33 | 58.33 | 33.33 | |
| Week 20 | 0.0 | 41.67 | 33.33 | |
| Week 24 | 0.0 | 41.67 | 33.33 | |
| Week 28 | 0.0 | 41.67 | 25.00 | |
| Week 32 | 0.0 | 16.67 | 16.67 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With 3-point Reduction in MGC Total Score

| | |
|-----------------|--|
| End point title | Percentage of Participants With 3-point Reduction in MGC Total Score |
|-----------------|--|

End point description:

The percentage of responders with at least a 3-point reduction in MGC total score from baseline is reported. MGC is an assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Each question is graded on 4 levels of impact from normal to severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Percentages are rounded off to whole number at the nearest decimal. Full Analysis Set included all randomised participants who had baseline and at least 1 post-baseline efficacy assessment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32

| End point values | TAK-079 Placebo- matching | TAK-079 300 mg | TAK-079 600 mg | |
|-----------------------------------|---------------------------------|-------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 12 | 12 | 12 | |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| Week 4 | 66.67 | 75.00 | 41.67 | |
| Week 6 | 83.33 | 66.67 | 58.33 | |
| Week 8 | 83.33 | 83.33 | 58.33 | |
| Week 10 | 83.33 | 75.00 | 50.00 | |
| Week 12 | 75.00 | 91.67 | 58.33 | |
| Week 14 | 66.67 | 83.33 | 50.00 | |
| Week 16 | 66.67 | 75.00 | 41.67 | |
| Week 20 | 0.0 | 75.00 | 58.33 | |
| Week 24 | 0.0 | 66.67 | 50.00 | |
| Week 28 | 0.0 | 58.33 | 50.00 | |
| Week 32 | 0.0 | 41.67 | 25.00 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From signing the informed consent form up to end of long-term follow-up (up to Week 32)

Adverse event reporting additional description:

At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Safety Analysis Set included participants who received at least 1 dose of study drug.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 25.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------------------|
| Reporting group title | TAK-079 Placebo-matching |
|-----------------------|--------------------------|

Reporting group description:

TAK-079 placebo-matching injection, SC, once weekly in combination with standard background therapy for 8 weeks.

| | |
|-----------------------|----------------|
| Reporting group title | TAK-079 600 mg |
|-----------------------|----------------|

Reporting group description:

TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.

| | |
|-----------------------|----------------|
| Reporting group title | TAK-079 300 mg |
|-----------------------|----------------|

Reporting group description:

TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.

| Serious adverse events | TAK-079 Placebo-matching | TAK-079 600 mg | TAK-079 300 mg |
|---|--------------------------|----------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 12 (8.33%) | 1 / 12 (8.33%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Myasthenia gravis | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Enteritis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|----------------|
| Psychiatric disorders | | | |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | TAK-079 Placebo-matching | TAK-079 600 mg | TAK-079 300 mg |
|---|--------------------------|------------------|-----------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 8 / 12 (66.67%) | 11 / 12 (91.67%) | 9 / 12 (75.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Fatigue | | | |

| | | | |
|-----------------------------|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 12 (0.00%) | 2 / 12 (16.67%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 3 | 1 |
| Early satiety | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 3 / 12 (25.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Feeling hot | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site haematoma | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injection site hypertrophy | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 3 / 12 (25.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 1 | 3 | 3 |
| Malaise | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site pain | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 5 |
| Immune system disorders | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| Immunisation reaction subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea exertional subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 1 / 12 (8.33%) 1 |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Psychiatric disorders | | | |
| Depression subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Investigations | | | |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Blood glucose increased subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Blood immunoglobulin A decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Lymphocyte count decreased subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| SARS-CoV-2 test positive | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Staphylococcus test positive subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Injury, poisoning and procedural complications Limb injury subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Cardiac disorders Atrioventricular block first degree subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Dysarthria subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Hypoaesthesia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Myasthenia gravis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Paraesthesia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Parosmia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Tension headache subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 2 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |

| | | | |
|---------------------------------|----------------|----------------|----------------|
| Anaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Normochromic normocytic anaemia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis allergic | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Diplopia | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Ocular hypertension | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Angle closure glaucoma | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vitreous detachment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Visual impairment | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| Vomiting subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 2 | 0 / 12 (0.00%) 0 |
| Odynophagia subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Rash papular subjects affected / exposed occurrences (all) | 1 / 12 (8.33%) 1 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Renal and urinary disorders | | | |
| Urine odour abnormal subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Muscular weakness subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Pain in jaw subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |
| Joint noise subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 12 (0.00%) 0 |

| | | | |
|------------------------------------|----------------|-----------------|----------------|
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal wall abscess | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Bartholin's abscess | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 2 / 12 (16.67%) | 0 / 12 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 12 (8.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|---|
| 04 March 2020 | Following changes were implemented with Protocol Amendment 2: -Updated inclusion criterion to clarify the intent to exclude only pulse steroid therapy. Dosing of corticosteroids with oral therapy every other day to be as acceptable as daily. -Updated exclusion criterion to exclude only those receiving live vaccines and not inactive vaccines. -Updated exclusion criterion to clarify the intent not to exclude a minor, benign, resolved, localized herpes simplex infection not requiring systemic therapy. -Updated exclusion criterion to change "lower limit of normal" to "5 g/L." As a result of this edit, participants were excluded if the IgG was less than 5 g/L (500 mg/dL) at screening. -Updated exclusion criterion to clarify the intent to exclude participants with active hepatitis C and not those who have been fully cured of the disease. Additionally, more stringent criteria were used to exclude participants with hepatitis B infection. -Updated the SAE reporting procedure to include an acknowledgement of receipt. -Added a global fax number to the SAE Reporting Contact Information. -Descriptors for circulating biomarker samples and quantitative immunoglobulin (Ig) A/IgM/IgG samples were changed from blood to serum. -Updated the version number of the QMG scoring assessment tool, which fixed a typographical error in the definition of severe forced vital capacity (FVC). -Serum samples for hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) were added to Primary Specimen Collection Table. -Added serum pregnancy test at Week 32. -Eligibility criteria regarding immunosuppressive drugs now required a stable dose for at least 3 months before screening. Stable dosing of azathioprine remained at 6 months prior to screening. |
| 28 September 2020 | Following changes were implemented with Protocol Amendment 3: Added contingency plans for the COVID-19 pandemic by incorporating flexibility for the study participants and investigators, while continuing to maintain participant safety and study integrity as per local site regulations. |
| 01 February 2021 | Following changes were implemented with Protocol Amendment 4: Clarified the intent of exclusion criterion. |
| 05 May 2021 | Following changes were implemented with Protocol Amendment 5: Changed the legal entity name for the sponsor to Takeda Development Center Americas, Inc., 95 Hayden Avenue, Lexington, MA 02421, USA. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported